Your browser doesn't support javascript.
loading
Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trial.
Hu, Yue-Mei; Huang, Shou-Jie; Chu, Kai; Wu, Ting; Wang, Zhong-Ze; Yang, Chang-Lin; Cai, Jia-Ping; Jiang, Han-Min; Wang, Yi-Jun; Guo, Meng; Liu, Xiao-Hui; Huang, Hong-Jiang; Zhu, Feng-Cai; Zhang, Jun; Xia, Ning-Shao.
Afiliação
  • Hu YM; Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.
  • Huang SJ; National Institute of Diagnostics and Vaccine Development in Infectious Diseases; School of Public Health; Xiamen University; Xiamen, PR China.
  • Chu K; Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.
  • Wu T; National Institute of Diagnostics and Vaccine Development in Infectious Diseases; School of Public Health; Xiamen University; Xiamen, PR China.
  • Wang ZZ; Dongtai Center for Disease Control and Prevention; Dongtai, Jiangsu Province, PR China.
  • Yang CL; Dongtai Center for Disease Control and Prevention; Dongtai, Jiangsu Province, PR China.
  • Cai JP; Dongtai Center for Disease Control and Prevention; Dongtai, Jiangsu Province, PR China.
  • Jiang HM; Dongtai Center for Disease Control and Prevention; Dongtai, Jiangsu Province, PR China.
  • Wang YJ; Dongtai Center for Disease Control and Prevention; Dongtai, Jiangsu Province, PR China.
  • Guo M; Xiamen Innovax Biotech Company, Ltd.; Xiamen, PR China.
  • Liu XH; Xiamen Innovax Biotech Company, Ltd.; Xiamen, PR China.
  • Huang HJ; Xiamen Innovax Biotech Company, Ltd.; Xiamen, PR China.
  • Zhu FC; Jiangsu Provincial Center for Disease Control and Prevention; Nanjing, Jiangsu Province, PR China.
  • Zhang J; National Institute of Diagnostics and Vaccine Development in Infectious Diseases; School of Public Health; Xiamen University; Xiamen, PR China.
  • Xia NS; National Institute of Diagnostics and Vaccine Development in Infectious Diseases; School of Public Health; Xiamen University; Xiamen, PR China.
Hum Vaccin Immunother ; 10(2): 469-75, 2014.
Article em En | MEDLINE | ID: mdl-24161937
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Proteínas Oncogênicas Virais / Proteínas do Capsídeo / Escherichia coli / Vacinas contra Papillomavirus / Vacinas de Partículas Semelhantes a Vírus Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Hum Vaccin Immunother Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Proteínas Oncogênicas Virais / Proteínas do Capsídeo / Escherichia coli / Vacinas contra Papillomavirus / Vacinas de Partículas Semelhantes a Vírus Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Middle aged País/Região como assunto: Asia Idioma: En Revista: Hum Vaccin Immunother Ano de publicação: 2014 Tipo de documento: Article